<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01170364</url>
  </required_header>
  <id_info>
    <org_study_id>5821</org_study_id>
    <nct_id>NCT01170364</nct_id>
  </id_info>
  <brief_title>Studying the Effects of Sibutramine on Eating Behavior</brief_title>
  <official_title>Studying the Effects of Sibutramine on Eating Behavior</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a major public health concern, and the search for useful pharmacologic
      interventions is ongoing. This study aims to develop a comprehensive series of assessments to
      directly assess eating behavior, cognitive functioning, and psychological functioning under
      sibutramine and placebo conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit 48 moderately obese men and women seeking weight-loss treatment to
      participate in a 3-week, randomized, double-blind, cross-over trial of sibutramine 15mg or
      placebo daily. At the end of weeks 1 and 3, subjects will be asked to participate in a
      two-day/three-night stay in the Residential Laboratory or Biological Studies Unit of the New
      York State Psychiatric Institute for comprehensive assessments. The major outcome variable
      will be the difference in total daily caloric intake between sibutramine and placebo.

      Assessments will concentrate on three main components of eating behavior: eating patterns,
      psychological processing, and neurocognitive function. Eating behavior studies will examine
      objective variables such as meal size, meal frequency, and subjective aspects of eating such
      as hunger and fullness. Psychological studies will measure hedonics, including craving,
      behavioral restraint, and impulsivity. Neurocognitive function assessment will gather
      information about decision-making, such as the effects of distractors (food and non-food) on
      task performance. Additionally, drawing from the field of behavioral neuroeconomics, tasks
      that assess decision-making and the influence of irrational factors on decisions will be
      assessed. Neuroimaging (fMRI) procedures will also be conducted, and will augment the
      psychological and neurocognitive assessments by providing a window into the underlying neural
      circuitry involved.

      Following the double-blind phase, participants will be offered open treatment with
      sibutramine for weight loss.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to sibutramine being withdrawn from the market.
  </why_stopped>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 Hour Measured Caloric Intake</measure>
    <time_frame>1 week</time_frame>
    <description>The primary outcome measure is 24-hour food intake assessed by 24 hour weighed intake after one week of sibutramine administration compared to one week of placebo administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Sibutramine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm receive sibutramine 15mg for one week followed by two weeks of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants are prescribed two weeks of placebo, followed by one week of 15mg sibutramine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sibutramine</intervention_name>
    <description>1 week of active sibutramine (15mg)</description>
    <arm_group_label>Sibutramine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Meridia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 weeks of placebo</description>
    <arm_group_label>Sibutramine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderately obese

          -  stable weight for a minimum of 3 months

          -  systolic blood pressure less than or equal to 140 mm Hg

          -  diastolic blood pressure less than or equal to 90 mm Hg

          -  pulse less than or equal to 95 beats per minute

          -  English language proficiency

        Exclusion Criteria:

          -  on medications known to affect appetite, weight, or metabolism

          -  current or past history of: binge eating disorder, anorexia nervosa or bulimia
             nervosa, major depression

          -  current or past evidence of psychosis, bipolar illness

          -  current or past history of alcohol or drug abuse or dependence

          -  known history of learning disorder or developmental disability

          -  current or past attention deficit hyperactivity disorders

          -  low platelet count

          -  current diabetes mellitus

          -  uncontrolled asthma, or controlled only with oral steroids

          -  hypothyroidism not adequately treated

          -  pregnancy, planning to become pregnant, or lactation within the previous 6 months

          -  history of neurological disorder or injury

          -  history of moderate or severe head injury

          -  waist circumference greater than 188 cm

          -  indwelling metallic object, non-removable metal jewelery, medicinal patch or recent
             metallic ink tattoo

          -  pacemaker

          -  metallic implants

          -  medication patches

          -  significant claustrophobia

          -  color blindness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurel Mayer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2010</study_first_submitted>
  <study_first_submitted_qc>July 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2010</study_first_posted>
  <results_first_submitted>December 13, 2012</results_first_submitted>
  <results_first_submitted_qc>July 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 31, 2017</results_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>sibutramine</keyword>
  <keyword>eating behavior</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sibutramine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>45 potential participants were screened for eligibility between February, 2009 and July 2010 at an academic medical center in New York City, NY.</recruitment_details>
      <pre_assignment_details>14 of 45 patients were randomized. Of those not randomized, 21 did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sibutramine First, Then Placebo</title>
          <description>This is a cross over design study. Participants in this arm begin with one week of 15mg sibutramine, followed by two weeks of placebo.</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Sibutramine</title>
          <description>This is a cross over design study. Participants in this arm begin with two weeks of placebo, followed by one week of 15mg of sibutramine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5">One participant was unable to begin the second testing period due to scheduling conflicts.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sibutramine First, Then Placebo</title>
          <description>Participants in this group were randomized to begin with 7 days of 15mg of sibutramine, followed by 14 days of placebo.</description>
        </group>
        <group group_id="B2">
          <title>Placebo First, Then Sibutramine</title>
          <description>Participants in this group were randomized to begin with 14 days of placebo, followed by 7 days of 15mg of sibutramine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33" spread="6"/>
                    <measurement group_id="B2" value="39" spread="11"/>
                    <measurement group_id="B3" value="36" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24 Hour Measured Caloric Intake</title>
        <description>The primary outcome measure is 24-hour food intake assessed by 24 hour weighed intake after one week of sibutramine administration compared to one week of placebo administration.</description>
        <time_frame>1 week</time_frame>
        <population>This is a cross over design study. All participants received sibutramine and placebo. The sibutramine arm listed here includes all participants who received sibutramine (regardless of whether they received it first or second). The placebo arm included all those who received placebo (regardless of whether they received it first or second).</population>
        <group_list>
          <group group_id="O1">
            <title>Sibutramine</title>
            <description>In this arm, participants received sibutramine 15mg for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>In this arm, participants received placebo (for 15mg sibumtramine) for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>24 Hour Measured Caloric Intake</title>
          <description>The primary outcome measure is 24-hour food intake assessed by 24 hour weighed intake after one week of sibutramine administration compared to one week of placebo administration.</description>
          <population>This is a cross over design study. All participants received sibutramine and placebo. The sibutramine arm listed here includes all participants who received sibutramine (regardless of whether they received it first or second). The placebo arm included all those who received placebo (regardless of whether they received it first or second).</population>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1923" spread="655"/>
                    <measurement group_id="O2" value="2373" spread="774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.004</p_value>
            <method>paired sample t-test, two tailed</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One week for each intervention.</time_frame>
      <desc>At assessment visits, participants were asked about the presence or absence of 22 common medication side effects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sibutramine</title>
          <description>Participants who received sibutramine 15mg capsule every morning for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants who received a placebo capsule (matching sibutramine 15mg) every morning for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>irregular heartbeat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>sour taste</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>difficulty sitting still</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>tremor or shakiness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>trouble sleeping</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination of the study given the withdrawal of sibutramine from the US market.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Laurel Mayer</name_or_title>
      <organization>NYPInstitute</organization>
      <phone>646-774-8067</phone>
      <email>lsm16@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

